Page last updated: 2024-10-22

anastrozole and Metastase

anastrozole has been researched along with Metastase in 52 studies

Research Excerpts

ExcerptRelevanceReference
"We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy."9.30Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2019)
"We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC)."9.27Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, ( Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J, 2018)
"After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane."9.17Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013)
"The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard."9.16Combination anastrozole and fulvestrant in metastatic breast cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2012)
"This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)."9.14Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010)
"To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane."9.10Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? ( Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R, 2003)
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment."9.10Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. ( Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A, 2002)
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment."9.10Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. ( Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A, 2002)
" Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases."8.82A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003)
"In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol."8.80Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000)
"To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment."7.75Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009)
"To examine retrospectively the difference in efficacy by the AI sequence when anastrozole ( ANA) and exemestane (EXE) are clinically administered sequentially for patients with metastatic breast cancer."7.74[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]. ( Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y, 2008)
"We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department."7.72[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004)
"At the interim analysis, 359 patients were randomized and received anastrozole in combination with AZD8931 20 mg (n = 118), 40 mg (n = 120), or placebo (n = 121); 39 % of patients (n = 141) had a progression event."6.82Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. ( Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M, 2016)
"Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years."6.42Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003)
"Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen."6.42Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004)
"Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings."5.33Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. ( Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P, 2006)
"We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy."5.30Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Linden, HH; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2019)
"We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC)."5.27Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, ( Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J, 2018)
"After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation is no better than either fulvestrant alone or exemestane."5.17Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr ( Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D, 2013)
"The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard."5.16Combination anastrozole and fulvestrant in metastatic breast cancer. ( Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA, 2012)
"Bevacizumab combined with either anastrozole or fulvestrant was feasible and active in the first-line treatment of patients who have hormone receptor-positive metastatic breast cancer."5.15Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. ( Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA, 2011)
"This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)."5.14Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. ( Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C, 2010)
"To explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor-positive, metastatic breast cancer who have been rendered functionally postmenopausal with the use of the luteinizing hormone-releasing hormone agonist, goserelin."5.14Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. ( Arun, B; Carlson, RW; Chiv, VY; Chung, CT; Dice, K; Green, M; Phan, SC; Rivera, E; Schurman, CM; Theriault, R; Valero, V, 2010)
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment."5.10Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. ( Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A, 2002)
"To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and exemestane, EXE), we evaluated the clinical benefit (CB) in postmenopausal breast cancer patients, who had previously received anastrozole and subsequently formestane."5.10Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? ( Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R, 2003)
"To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment."5.10Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. ( Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A, 2002)
"Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy."4.82A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003)
" For more than 20 years, standard first-line treatment for postmenopausal women with metastatic breast cancer has been the antiestrogen tamoxifen, a selective estrogen receptor modulator (SERM) with differential effects on breast, endometrial, bone, and vascular tissues."4.82Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. ( Brodie, AH; Mouridsen, HT, 2003)
" Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases."4.82A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003)
" In women with hormone-sensitive breast cancer, three of these agents, letrozole, anastrozole, and exemestane, provide an important alternative endocrine therapy to the antiestrogen tamoxifen, which blocks estrogen activation of the estrogen receptor."4.82Aromatase inhibitors in advanced breast cancer. ( Mouridsen, HT, 2004)
"During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion."4.81[Antiestrogen therapy in the treatment of breast neoplasms]. ( Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G, 2002)
"Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen)."4.80The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. ( Hamilton, A; Piccart, M, 1999)
"In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol."4.80Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000)
"A total of 148 postmenopausal women (including bilateral ovariectomy) with hormone dependent metastatic breast cancer receiving aromatase inhibitors (letrozole, anastrozole or exemestane) were analyzed retrospectively."3.81[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases]. ( Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M, 2015)
"To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment."3.75Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. ( Barker, LC; Brand, IR; Crawford, SM, 2009)
"To examine retrospectively the difference in efficacy by the AI sequence when anastrozole ( ANA) and exemestane (EXE) are clinically administered sequentially for patients with metastatic breast cancer."3.74[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]. ( Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y, 2008)
"We reviewed therapeutic effects and harmful side effects in 33 patients with advanced or recurrent breast cancer who underwent treatment with Anastrozole 1 mg/day in our department."3.72[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]. ( Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K, 2004)
"At the interim analysis, 359 patients were randomized and received anastrozole in combination with AZD8931 20 mg (n = 118), 40 mg (n = 120), or placebo (n = 121); 39 % of patients (n = 141) had a progression event."2.82Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. ( Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M, 2016)
"Type I endometrial cancer is a common tumor of the female genital tract."2.53Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma. ( Babilonti, L; Bogliolo, S; Cassani, C; De Silvestri, A; Dominoni, M; Gaggero, CR; Gardella, B; Musacchi, V; Spinillo, A; Zanellini, F, 2016)
"The natural history of HR+ breast cancer tends to be different from hormone receptor-negative disease in terms of time to recurrence, site of recurrence and overall aggressiveness of the disease."2.50Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. ( Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ, 2014)
"Fulvestrant (Faslodex) is a novel estrogen receptor (ER) antagonist that competitively binds to the ER with a much greater affinity than that of tamoxifen."2.42Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. ( Curran, MP; McKeage, K; Plosker, GL, 2004)
"Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive breast cancer for nearly 20 years."2.42Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. ( Carlson, RW; Henderson, IC, 2003)
"The primary end point was distant metastasis (DM)."1.39The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. ( Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE, 2013)
"This case is an example of breast cancer presenting with paraneoplastic manifestations."1.35A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report. ( Cheung, KL; Haynes, AP; Wood, JP, 2008)
"The San Antonio Breast Cancer Symposium is now considered the most important international breast cancer meeting worldwide."1.33Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004. ( Ponzone, R; Sismondi, P, 2005)
"Metastatic breast cancer (MBC) is incurable in most cases."1.33Does survival increase in metastatic breast cancer with recently available anticancer drugs? ( Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F, 2006)
"Endocrine therapy for hormone-sensitive breast cancer is a well-established treatment option, both in adjuvant and palliative settings."1.33Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. ( Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P, 2006)

Research

Studies (52)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (5.77)18.2507
2000's24 (46.15)29.6817
2010's23 (44.23)24.3611
2020's2 (3.85)2.80

Authors

AuthorsStudies
Edmondson, RJ1
O'Connell, RL1
Banerjee, S1
Mileshkin, L1
Sykes, P1
Beale, P1
Fisher, A1
Bonaventura, A1
Millan, D1
Nottley, S1
Benson, C1
Hamilton, A2
Sjoquist, K1
Alexander, L1
Kelly, C1
Carty, K1
Divers, L1
Bradshaw, N1
Friedlander, M1
Maguire, M1
Drumm, C1
Woods, G1
Mullally, W1
Redmond, M1
Grogan, L1
O'Kane, M1
Wagner, LI1
Zhao, F1
Goss, PE1
Chapman, JW1
Shepherd, LE1
Whelan, TJ1
Mattar, BI1
Bufill, JA1
Schultz, WC1
LaFrancis, IE1
Nagargoje, GG1
Vemuri, R1
Nikcevich, DA1
Sledge, GW2
Cella, D1
Kim, JY1
Im, SA1
Jung, KH1
Ro, J1
Sohn, J1
Kim, JH1
Park, YH1
Kim, TY1
Kim, SB1
Lee, KS1
Kim, GM1
Kim, SH1
Kim, S1
Ahn, JS1
Lee, KH1
Ahn, JH1
Park, IH1
Im, YH2
Mehta, RS2
Barlow, WE2
Albain, KS2
Vandenberg, TA2
Dakhil, SR2
Tirumali, NR2
Lew, DL2
Hayes, DF2
Gralow, JR2
Linden, HH1
Livingston, RB2
Hortobagyi, GN3
Burki, TK1
Johnston, SR1
Kilburn, LS1
Ellis, P1
Dodwell, D1
Cameron, D1
Hayward, L1
Braybrooke, JP1
Brunt, AM1
Cheung, KL2
Jyothirmayi, R1
Robinson, A1
Wardley, AM1
Wheatley, D1
Howell, A3
Coombes, G1
Sergenson, N1
Sin, HJ1
Folkerd, E1
Dowsett, M2
Bliss, JM1
Dubsky, P1
Brase, JC1
Jakesz, R1
Rudas, M1
Singer, CF1
Greil, R1
Dietze, O1
Luisser, I1
Klug, E1
Sedivy, R1
Bachner, M1
Mayr, D1
Schmidt, M1
Gehrmann, MC1
Petry, C1
Weber, KE1
Fisch, K1
Kronenwett, R1
Gnant, M1
Filipits, M1
Campos-Gómez, S1
Flores-Arredondo, JH1
Dorantes-Heredia, R1
Chapa-Ibargüengoitia, M1
de la Peña-Lopez, R1
Dalmau, E1
Armengol-Alonso, A1
Muñoz, M1
Seguí-Palmer, MÁ1
Bogliolo, S1
Gardella, B1
Dominoni, M1
Musacchi, V1
Cassani, C1
Zanellini, F1
De Silvestri, A1
Gaggero, CR1
Babilonti, L1
Spinillo, A1
Zhang, M1
Yan, M1
Lü, H1
Niu, L1
Zeng, H1
Cui, S1
Beauchemin, C1
Letarte, N1
Mathurin, K1
Yelle, L1
Lachaine, J1
Sansone, P1
Ceccarelli, C1
Berishaj, M1
Chang, Q1
Rajasekhar, VK1
Perna, F1
Bowman, RL1
Vidone, M1
Daly, L1
Nnoli, J1
Santini, D1
Taffurelli, M1
Shih, NN1
Feldman, M1
Mao, JJ1
Colameco, C1
Chen, J1
DeMichele, A1
Fabbri, N1
Healey, JH1
Cricca, M1
Gasparre, G1
Lyden, D1
Bonafé, M1
Bromberg, J1
Johnston, S1
Basik, M1
Hegg, R1
Lausoontornsiri, W1
Grzeda, L1
Clemons, M1
Dreosti, L1
Mann, H1
Stuart, M1
Cristofanilli, M2
Ellis, MJ1
Suman, VJ1
Hoog, J1
Goncalves, R1
Sanati, S1
Creighton, CJ1
DeSchryver, K1
Crouch, E1
Brink, A1
Watson, M1
Luo, J1
Tao, Y1
Barnes, M1
Budd, GT1
Winer, E1
Silverman, P1
Esserman, L1
Carey, L1
Ma, CX1
Unzeitig, G1
Pluard, T1
Whitworth, P1
Babiera, G1
Guenther, JM1
Dayao, Z1
Ota, D1
Leitch, M1
Olson, JA1
Allred, DC1
Hunt, K1
Wood, JP1
Haynes, AP1
Barker, LC1
Brand, IR1
Crawford, SM1
Kaufman, B1
Mackey, JR1
Clemens, MR1
Bapsy, PP1
Vaid, A1
Wardley, A1
Tjulandin, S1
Jahn, M1
Lehle, M1
Feyereislova, A1
Révil, C1
Jones, A1
Doyen, J1
Italiano, A1
Largillier, R1
Ferrero, JM1
Fontana, X1
Thyss, A1
Valero, V2
Mangalik, A1
Royce, M1
Rabinowitz, I1
Arena, FP1
Kroener, JF1
Curcio, E1
Watkins, C1
Bacus, S1
Cora, EM1
Anderson, E1
Magill, PJ1
Carlson, RW3
Theriault, R1
Schurman, CM1
Rivera, E1
Chung, CT1
Phan, SC1
Arun, B1
Dice, K1
Chiv, VY1
Green, M1
Harris, CA1
Ward, RL1
Dobbins, TA1
Drew, AK1
Pearson, S1
Doughty, JC1
Yardley, DA1
Burris, HA1
Clark, BL1
Shipley, D1
Rubin, M1
Barton, J1
Arrowsmith, E1
Hainsworth, JD1
Cruz Jurado, J1
Richart Aznar, P1
García Mata, J1
Fernández Martínez, R1
Peláez Fernández, I1
Sampedro Gimeno, T1
Galve Calvo, E1
Murillo Jaso, L1
Polo Marqués, E1
García Palomo, A1
O'Neill, A1
Vidaurre, T1
Gomez, HL1
Badve, SS1
Osborne, CK1
Pippen, J1
Jones, SE1
Parker, LM1
Ellis, M1
Come, S1
Gertler, SZ1
May, JT1
Burton, G1
Dimery, I1
Webster, A2
Morris, C2
Elledge, R1
Buzdar, A1
Robertson, JF2
Quaresma Albano, J1
Aschermannova, A1
Mauriac, L1
Kleeberg, UR1
Vergote, I2
Erikstein, B1
Miyoshi, Y1
Taguchi, T1
Tamaki, Y1
Noguchi, S1
Brodie, AH1
Mouridsen, HT2
Rose, C1
Carlini, P1
Ferretti, G1
Di Cosimo, S1
Colella, E1
Tonachella, R1
Romiti, A1
Tomao, S1
Frassoldati, A1
Papaldo, P1
Fabi, A1
Ruggeri, EM1
Cognetti, F1
Mouridsen, H1
Gershanovich, M1
Henderson, IC1
McKeage, K1
Curran, MP1
Plosker, GL1
Okubo, S1
Sonoo, H2
Hirono, M1
Nomura, T2
Udagawa, K1
Ikeda, M2
Nakashima, K2
Tanaka, K2
Kurebayashi, J2
Ponzone, R1
Sismondi, P1
Abrial, C1
Leheurteur, M1
Cabrespine, A1
Mouret-Reynier, MA1
Durando, X1
Ferriere, JP1
Kwiatkowski, F1
Penault-Llorca, F1
Cure, H1
Chollet, P1
Langenegger, T1
Wahl, P1
Schiesser, D1
Thürlimann, B1
El-Saghir, NS1
El-Hajj, II1
Makarem, JA1
Otrock, ZK1
Herold, CI1
Blackwell, KL1
Miyake, A1
Yamamoto, Y1
Shiiki, S1
Buzdar, AU1
Plourde, PV1
Piccart, M1
Messori, A1
Cattel, F1
Trippoli, S1
Vaiani, M1
Winer, EP1
Burstein, HJ1
Alba, E1
Ragonesi, G1
Colla, F1
Mazzoleni, A1
Farina, C1

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman[NCT01266213]Phase 2147 participants (Anticipated)Interventional2010-12-31Active, not recruiting
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer[NCT00075764]Phase 3695 participants (Actual)Interventional2004-04-30Completed
A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex™) With or Without Concomitant Anastrozole (Arimidex™) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-[NCT00253422]Phase 3750 participants (Anticipated)Interventional2004-03-31Active, not recruiting
A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-st[NCT00944918]Phase 325 participants (Actual)Interventional2008-12-31Completed
Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study[NCT03503799]1,191 participants (Actual)Observational [Patient Registry]2018-07-17Active, not recruiting
A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Th[NCT01151215]Phase 2482 participants (Actual)Interventional2010-06-30Terminated (stopped due to Futility)
A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer[NCT00265759]Phase 3622 participants (Actual)Interventional2006-01-31Completed
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study[NCT01953588]Phase 31,473 participants (Actual)Interventional2013-12-13Active, not recruiting
Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer[NCT04895761]Phase 16 participants (Actual)Interventional2021-09-10Active, not recruiting
Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268]Phase 2104 participants (Anticipated)Interventional2022-03-11Recruiting
Phase II Study of Pyrotinib in Combination With Fulvestrant in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive,Hormone Receptor(HR)-Positive Metastatic Breast Cancer[NCT04034589]Phase 246 participants (Anticipated)Interventional2019-07-17Recruiting
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positi[NCT03644186]Phase 2144 participants (Actual)Interventional2019-04-16Completed
A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women[NCT00186121]Phase 235 participants (Actual)Interventional2000-10-31Completed
A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients)[NCT00405938]Phase 279 participants (Actual)Interventional2006-11-30Completed
A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic [NCT00057941]Phase 2148 participants (Actual)Interventional2003-09-30Completed
A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496]Phase 3396 participants (Anticipated)Interventional2007-11-30Recruiting
A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice[NCT01425294]231 participants (Actual)Observational2011-08-01Terminated (stopped due to The study has been decided to be early terminated for the FAS 500 mg has launched in 2015. The use mothod of 250mg per month in clinical practice is off-label.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Clinical Benefit (CR, PR, Confirmed or Unconfirmed, or Stable Disease >= 24 Weeks).

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable, Does not qualify for CR, PR, Progression or Symptomatic Deterioration. Clinical Benefit = CR + PR + Stable >= 24 weeks (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.

Interventionpercentage of participants (Number)
Arm I Anastrozole70
Arm II Anastrozole and Fulvestrant73

Overall Survival

From date of randomization to date of death due to any cause. Patients last known to be alive are censored at last date of contact. (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.

Interventionmonths (Median)
Arm I Anastrozole41.3
Arm II Anastrozole and Fulvestrant47.7

Time to Tumor Progression

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration. From date of randomization to time of first documentation of progression, symptomatic deterioration or death due to any cause. Patients last known to be alive and progression free are considered at last date of contact. (NCT00075764)
Timeframe: Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.

Interventionmonths (Median)
Arm I Anastrozole13.5
Arm II Anastrozole and Fulvestrant15.0

Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs

Adverse Events (AEs) are reported by CTCAE version 3.0 terminology. For each patient, worst grade of each event type is reported. Grade3 (Severe), Grade4 (Life-threatening), Grade 5 (Fatal) (NCT00075764)
Timeframe: Patients were assessed for adverse events after each cycle (1 cycle = 28 days) while on treatment.

,
InterventionParticipants (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST, SGOTAlbumin, serum-low (hypoalbuminemia)Alkaline phosphataseAnorexiaBilirubin (hyperbilirubinemia)CNS cerebrovascular ischemiaCalcium, serum-high (hypercalcemia)CataractConfusionConstipationDehydrationDiarrheaDizzinessDyspnea (shortness of breath)Edema: limbFatigue (asthenia, lethargy, malaise)Febrile neutropeniaFractureGlucose, serum-high (hyperglycemia)HemoglobinHemolysisHot flashes/flushesHypertensionInf w/normal ANC or Gr 1-2 neutrophils - BloodInf w/normal ANC or Gr 1-2 neutrophils - UTIInfection with unknown ANC - Urinary tract NOSInsomniaJoint-effusionLeukocytes (total WBC)LymphopeniaMemory impairmentMood alteration - agitationMood alteration - anxietyMood alteration - depressionMucositis/stomatitis (functional/symp) - PharynxMuscle weakness, not d/t neuropathy - body/generalNauseaNeurology-Other (Specify)Neuropathy: sensoryNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - BackPain - BonePain - BreastPain - ButtockPain - Chest wallPain - Chest/thorax NOSPain - Extremity-limbPain - Head/headachePain - JointPain - MusclePain - NeckPain - PelvisPain-Other (Specify)PlateletsRash/desquamationSodium, serum-low (hyponatremia)Speech impairment (e.g., dysphasia or aphasia)Sudden deathSyncope (fainting)Thrombosis/embolism (vascular access-related)Thrombosis/thrombus/embolismTinnitusTumor flareUrticaria (hives, welts, wheals)VomitingWeight gain
Arm I Anastrozole13110101101121117111112211000031010113110151110101530022101003600030
Arm II Anastrozole and Fulvestrant11101020111112119022317101212130103001002271001130701312110111712121

Compare the Overall Survival in Patients Treated With AZD8931 in Combination With Anastrozole Versus Anastrozole Alone

Time from the date of randomization to the date of death (by any cause) (NCT01151215)
Timeframe: Following progression, patients were contacted at 12 weekly intervals until data cut-off at 31 August 2012 to determine survival status

InterventionMonths (Median)
AZD8931 40mg + Anastrozole 1mg6.9
AZD8931 20mg + Anastrozole 1mg8.3
Placebo + Anastrozole 1mg7.9

Progression Free Survival as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1

Time from the date of randomization until the date of objective disease progression (as per RECIST 1.1) or the date of death (by any cause in the absence of progression). Disease progression is defined using RECIST 1.1 as >=20% increase in the sum of longest diameters of target lesions and an absolute increase of >=5mm, taking as reference the smallest sum of longest diameters of target lesions since study start, or unequivocal progression in non-target lesions, or appearance of any new lesions. (NCT01151215)
Timeframe: Tumour assessment by RECIST 1.1 every 12 weeks until data cut-off at 31 August 2012

InterventionMonths (Median)
AZD8931 40mg + Anastrozole 1mg13.8
AZD8931 20mg + Anastrozole 1mg10.9
Placebo + Anastrozole 1mg14.0

Anti-tumor Effect in Terms of Pathologic CR (pCR) Rate to Neoadjuvant Chemotherapy (Cohort B)

The primary aim is to assess the anti-tumor effect in terms of pathologic CR rates of neo-adjuvant chemotherapy in patients with T2-T4c, any N, M0 breast cancer (by clinical staging) who are endocrine therapy resistant (that is, their Ki-67 level is >10 after 2-4 week of neo-adjuvant endocrine therapy alone). The pCR rate (percentage) for neo-adjuvant chemotherapy is defined as 100 times the number of eligible patients with no histologic evidence of invasive tumor cells in the surgical breast specimen and the axillary or sentinel lymph nodes divided by the total number of eligible patients who received neo-adjuvant chemotherapy. (NCT00265759)
Timeframe: Up to 18 weeks

Interventionpercentage of patients (Number)
Cohort B Arm II: Week 2 Ki67 > 10%5.7

Clinical Response (Complete or Partial Response) Rate (Cohort A)

The clinical response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose disease meets the WHO criteria for complete or partial response prior to surgery divided by the total number of eligible patients randomized to that treatment. For each treatment arm, a 95% binomial confidence interval will be constructed for the true clinical response rate. Complete Response (CR): The disappearance of all known disease based on a comparison between the measurements at baseline and the Week 16 visit. Partial Response (PR): A 50% or greater decrease in the product of the bi-dimensional measurements of the lesion (total tumor size) based on a comparison between the measurements at baseline and the Week 16 visit. In addition there can be no appearance of new lesions or progression of any lesion. (NCT00265759)
Timeframe: Up to 18 weeks

Interventionpercentage of patients (Number)
Cohort A Arm I: Exemestane62.9
Cohort A Arm II: Letrozole74.8
Cohort A Arm III: Anastrozole69.1

Rate of Improved Surgical Outcome for Patients Considered Marginal for Breast Conservation Surgery Prior to Therapy (Cohort A)

The rate (percentage) of improved surgical outcome for patients considered marginal for breast conservation surgery prior to therapy for Cohort A is reported below for each treatment arm. Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks

Interventionpercentage of improved surgical outcome (Number)
Cohort A Arm I: Exemestane85.2
Cohort A Arm II: Letrozole77.4
Cohort A Arm III: Anastrozole86.4

Rate of Improved Surgical Outcome for Patients Designated as Candidates for Mastectomy Prior to Therapy (Cohort A)

Rate (percentage) of Improved surgical outcome for patients designated as candidates for mastectomy prior to therapy (Cohort A). Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks

Interventionpercentage of patients (Number)
Cohort A Arm I: Exemestane48.1
Cohort A Arm II: Letrozole42.1
Cohort A Arm III: Anastrozole60.0

Rate of Lymph Node Involvement (LNI) (Cohort A)

For those patients who undergo a sentinel lymph node dissection or an axillary lymph node dissection (at least 6 nodes examined with Hematoxylin & Eosin Staining), the LNI rate (percentage) is defined as 100 times the proportion of eligible patients randomized to that treatment with at least one positive node. For each neo-adjuvant endocrine treatment, a 95% binomial confidence interval will be constructed for its true LNI rate. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks

Interventionpercentage of patients (Number)
Cohort A Arm I: Exemestane41.1
Cohort A Arm II: Letrozole48.2
Cohort A Arm III: Anastrozole44.1

The Pathologic Complete Response (pCR) Rate (Cohort A)

The pathologic complete response is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes. The pathologic complete response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose surgical specimen is such that there is no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes divided by the total number of eligible patients randomized to that treatment. For each neo-adjuvant endocrine treatment pair, a 95% binomial confidence interval will be constructed for the true difference in the pCR between these 2 treatments. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks

Interventionpercentage of patients (Number)
Cohort A Arm I: Exemestane1.7
Cohort A Arm II: Letrozole0.0
Cohort A Arm III: Anastrozole0.0

Toxicity (Cohort A)

Incidence of the most common grade 3+ toxicities reported to be probably, possibly, or definitely related to treatment as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (Cohort A) At each treatment evaluation, the type, severity, and attribution of each adverse event reported will be assessed using the NCI-CTCAE definitions. For each treatment, the percentage of patients who developed a severe (grade 3+) toxicity considered possibly, probably or definitively related to treatment will be determined. (NCT00265759)
Timeframe: Up to 30 days after drug therapy

,,
Interventionpercentage of patients (Number)
FatigueHot flashes/flushesJoint pain
Cohort A Arm I: Exemestane222
Cohort A Arm II: Letrozole243
Cohort A Arm III: Anastrozole322

Clinical Benefit Rate

"The overall clinical benefit rate of goserelin followed by anastrozole was evaluated, as determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rate + Stable Disease (SD) rate.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Anastrozole + Goserelin71.9

Objective Response Rate (ORR)

"ORR was determined as the sum of the Complete Response (CR) rate + Partial Response (PR) rates.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 3 months

Interventionpercentage of participants (Number)
Anastrozole + Goserelin37.5

Overall Survival (OS)

Overall survival (OS) was assessed as the median observed in the participants receiving goserelin followed by anastrozole. (NCT00186121)
Timeframe: up to 63 months

Interventionmonths (Median)
Anastrozole + GoserelinNA

Serious Adverse Events

The toxicity of the treatment regimen of goserelin followed by anastrozole is estimated by the rate of Serious Adverse Events (SAEs) that occurred during the course of the study. (NCT00186121)
Timeframe: 6 months

InterventionSerious Adverse Events (SAEs) (Number)
Anastrozole + Goserelin0

Time-to-Progression (TTP)

"Time-to-progression (TTP) was assessed as the median observed in the participant group.~Progression of disease was considered, per protocol, to be ≤ 25% increase in the area of any malignant lesion greater than 2 square cm, or ≤ 25% increase in the sum of the products of the longest perpendicular diameters of individual lesions in a given organ, when compared to baseline values or after therapeutic response." (NCT00186121)
Timeframe: up to 63 months

Interventionmonths (Median)
Anastrozole + Goserelin8.3

Estradiol Suppression

Plasma estradiol determinations were performed at baseline, 1 month, 3 months, and 6 months using the Coat-A-Count Estradiol competitive binding assay system, which has a calibrated range for estradiol of 20 to 3,600 pg/mL with an analytical sensitivity of 10 pg/mL. (NCT00186121)
Timeframe: 6 months

Interventionpg/mL estradiol (Mean)
Mean at BaselineMean at 1 month treatmentMean at 3 months treatmentMean at 6 months treatment
Anastrozole + Goserelin74.720.818.714.8

Response Rates

"The numbers of participants with metastatic breast cancer experiencing Complete Response (CR); Partial Response (PR); or Stable Disease (SD) after treatment with goserelin followed by anastrozole are reported.~CR = Complete disappearance of all clinically- or pathologically-detectable malignant disease for at least 4 weeks.~PR = ≥ 50% decrease in tumor size for at least 4 weeks, without any new lesion or any ≥ 25% increase in size of any lesion.~SD = No significant change in measurable or evaluable disease for at least 4 weeks.~All measurements by ruler or calipers." (NCT00186121)
Timeframe: 6 months

InterventionParticipants (Count of Participants)
Complete Response (CR)Partial Response (PR)Stable Disease (SD)
Anastrozole + Goserelin11111

Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment

The Percentage of Patients Who Experience an Objective Benefit From Treatment (CR+PR). The response categories were assigned using RECIST criteria. Complete Response (CR) = Disappearance of all target lesions ; Partial Response (PR) = >=30% decrease in the sum of the longest diameter of target lesions. (NCT00405938)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Bevacizumab/Anastrozole18
Bevacizumab/Fulvestrant11

Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease

Progression Free Survival (PFS) is defined as the interval, in months, from the date of first treatment to the date of disease progression or death, whichever occurred first. (NCT00405938)
Timeframe: 18 months

Interventionmonths (Median)
Bevacizumab/Anastrozole21
Bevacizumab/Fulvestrant9

Clinical Benefit Rate

Clinical benefit = complete response (CR), partial response (PR), or stable disease (SD) lasting for at least 6 months, assessed per Response Evaluation Criteria of Solid Tumor (RECIST).CR=disappearance of all target and non-target lesions. PR= disappearance of or at least 30% decrease in the sum of the longest diameters of target lesions, with non-progressive disease in non-target lesions. SD= sum of the longest diameters of target lesions decrease <30% or increase <20%, with non-progressive disease in non-target lesions. 141 eligible, treated patients were included. (NCT00057941)
Timeframe: assessed every 3 cycles while on treatment, assessed every 3 months when follow up <2 years, every 6 months between 2-3 years,no specific requirements after 3 years

Interventionpercentage of participants (Number)
Anastrozole and ZD183944
Fulvestrant and ZD183941

Reviews

18 reviews available for anastrozole and Metastase

ArticleYear
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistanc

2014
Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma.
    Archives of gynecology and obstetrics, 2016, Volume: 293, Issue:4

    Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometria

2016
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:6

    Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2011
When to start an aromatase inhibitor: now or later?
    Journal of surgical oncology, 2011, Jun-01, Volume: 103, Issue:7

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Adm

2011
Management of patients with metastatic breast cancer.
    Advances in therapy, 2011, Volume: 28 Suppl 6

    Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disea

2011
Current status of endocrine therapy for breast cancer.
    Breast cancer (Tokyo, Japan), 2003, Volume: 10, Issue:2

    Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemoth

2003
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

2003
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast

2003
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 14

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms

2003
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Breast cancer research and treatment, 2003, Volume: 80 Suppl 1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Adminis

2003
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
    Breast cancer research and treatment, 2003, Volume: 82, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic;

2003
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    Drugs, 2004, Volume: 64, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol;

2004
Aromatase inhibitors in advanced breast cancer.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 12

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female;

2004
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
    Breast (Edinburgh, Scotland), 2008, Volume: 17 Suppl 1

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms

2008
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms;

1999
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
    Anti-cancer drugs, 2000, Volume: 11, Issue:9

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib

2000
New combinations with Herceptin in metastatic breast cancer.
    Oncology, 2001, Volume: 61 Suppl 2

    Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo

2001
[Antiestrogen therapy in the treatment of breast neoplasms].
    Minerva ginecologica, 2002, Volume: 54, Issue:3

    Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br

2002

Trials

15 trials available for anastrozole and Metastase

ArticleYear
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
    Gynecologic oncology, 2021, Volume: 163, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Carcinosarcoma; Female; Humans; L

2021
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 103

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols;

2018
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
    The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata

2019
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
    The Lancet. Oncology, 2013, Volume: 14, Issue:10

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease

2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
    The Lancet. Oncology, 2013, Volume: 14, Issue:10

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease

2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
    The Lancet. Oncology, 2013, Volume: 14, Issue:10

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease

2013
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
    The Lancet. Oncology, 2013, Volume: 14, Issue:10

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease

2013
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
    Breast cancer research and treatment, 2016, Volume: 160, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast

2016
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit

2017
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal;

2009
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal;

2009
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal;

2009
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal;

2009
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast

2010
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Sep-01, Volume: 28, Issue:25

    Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Fem

2010
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
    Clinical breast cancer, 2011, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz

2011
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
    Breast cancer research and treatment, 2012, Volume: 133, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast

2012
Combination anastrozole and fulvestrant in metastatic breast cancer.
    The New England journal of medicine, 2012, Aug-02, Volume: 367, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata

2012
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-15, Volume: 20, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dise

2002
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:1

    Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase

2003

Other Studies

19 other studies available for anastrozole and Metastase

ArticleYear
A case of delayed-onset scarring alopecia in a 75-year-old woman.
    Clinical and experimental dermatology, 2020, Volume: 45, Issue:6

    Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast

2020
Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG
    Breast cancer research and treatment, 2018, Volume: 169, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Breast Neoplasms; Combined Modality The

2018
Fulvestrant plus anastrozole for metastatic breast cancer.
    The Lancet. Oncology, 2019, Volume: 20, Issue:5

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms;

2019
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
    British journal of cancer, 2013, Dec-10, Volume: 109, Issue:12

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast

2013
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
    BMC cancer, 2014, Sep-23, Volume: 14

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Ductal; Disease

2014
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
    Zhonghua yi xue za zhi, 2015, Jun-09, Volume: 95, Issue:22

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female;

2015
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
    Journal of medical economics, 2016, Volume: 19, Issue:6

    Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2016
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
    Nature communications, 2016, Feb-09, Volume: 7

    Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal;

2016
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
    World journal of surgical oncology, 2008, Dec-16, Volume: 6

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Creatine Kinase; Female; Humans; Immunoglobulin

2008
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
    Current medical research and opinion, 2009, Volume: 25, Issue:5

    Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endo

2009
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aroma

2010
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chol

2004
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2005
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
    Oncology research, 2006, Volume: 15, Issue:9

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Ne

2006
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
    Breast cancer research and treatment, 2006, Volume: 100, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast

2006
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    Anti-cancer drugs, 2006, Volume: 17, Issue:8

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoth

2006
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms;

2008
Anastrozole for metastatic breast cancer.
    The Medical letter on drugs and therapeutics, 1996, Jul-05, Volume: 38, Issue:978

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Met

1996
Aromatase inhibitors in metastatic breast cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:4 Suppl 9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Fem

1996